文献速递区域麻醉与超声疼痛医学术前评估与围术期医学

全关节置换术后缓释阿片类药物配药发生率、预后因素及变异的群体横断面分析

A Population-based Cross-sectional Analysis of Extended-release Opioid Dispensing Incidence, Prognostic Factors, and Variation after Total Joint Arthroplasty.
PubMed 文献 · Anesthesiology · 2026-04-22

该研究基于加拿大安大略省2013至2022年行政数据库,纳入258,642例初次全髋或膝关节置换术成人,发现12.1%患者在出院后7天内配取新缓释阿片类药物处方。多因素分析显示男性、术前阿片暴露及ASA III增加配药 odds,而椎管内麻醉、外周神经阻滞和急性疼痛服务参与具有保护作用。医院和外科医生层面变异显著,麻醉医生层面变异极小。

要点

  • 全髋/膝关节置换术后约12.1%患者出院后7天内配取新缓释阿片处方。
  • 椎管内麻醉、外周神经阻滞及急性疼痛服务参与与较低缓释阿片配药 odds 相关。
  • 配药变异主要来自医院和外科医生层面,麻醉医生层面变异极小。

核心结论

  • 每10例全髋或膝关节置换术后患者中约1例配取缓释阿片处方,该实践变异大且主要由机构和外科实践模式驱动,而非患者因素。

研究设计与样本

  • 基于加拿大安大略省关联行政数据库的群体横断面研究,纳入2013至2022年接受初次全髋或膝关节置换术的成人,共258,642例手术。

主要发现

  • 31,224例(12.1%)患者在出院后7天内配取新缓释阿片处方。
  • 男性(OR 1.14;95%CI 1.09-1.19)、术前阿片暴露评分2(OR 1.21;95%CI 1.15-1.27)和评分3(OR 1.38;95%CI 1.20-1.58)、ASA III(OR 1.07;95%CI 1.01-1.12)增加配药 odds。
  • 椎管内麻醉(OR 0.79;95%CI 0.74-0.84)、外周神经阻滞(OR 0.84;95%CI 0.79-0.89)和急性疼痛服务参与(OR 0.77;95%CI 0.70-0.85)降低配药 odds。
  • 医院层面变异 VPC 46%(95%CI 0.4-0.54),MOR 9.3(95%CI 6.57-15.27);外科医生层面 VPC 26%(95%CI 0.24-0.26),MOR 5.3(95%CI 4.63-6.11);麻醉医生层面 VPC 1%(95%CI 0.010-0.011),MOR 1.4(95%CI 1.36-1.46)。

临床怎么用

  • 麻醉科医生应优先采用椎管内麻醉、外周神经阻滞并推动急性疼痛服务参与,以降低术后缓释阿片配药。
  • 针对医院和外科层面的高变异,可探索机构层面阿片类药物管理和标准化出院协议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended-release opioids (EROs) are not recommended for acute postoperative pain, yet their prescribing persists. This study examined the incidence, predictors, and variation in ERO dispensing after total hip and knee arthroplasty. METHODS: This was a population-based cross-sectional study of adults undergoing primary total hip or knee arthroplasty between 2013 and 2022 using linked administrative databases in Ontario, Canada. The primary outcome was fulfillment of an ERO prescription within 7 days of discharge. Multilevel logistic regression estimated associations between patient, surgical, anesthetic, and hospital factors and filling an ERO prescription. Variation was quantified using variance partition coefficients (VPCs) and median odds ratios (MORs) with 95% CIs, based on random effects. RESULTS: Among 258,642 knee and hip arthroplasty procedures, 31,224 (12.1%) patients filled a new ERO prescription after discharge. Male sex (odds ratio [OR], 1.14; 95% CI, 1.09 to 1.19), preoperative opioid exposure (Opioid Naïve-Exposed-Tolerant score, 2; OR, 1.21; 95% CI, 1.15 to 1.27; Opioid Naïve-Exposed-Tolerant score, 3; OR, 1.38; 95% CI, 1.20 to 1.58), and American Society of Anesthesiologists status of III (OR, 1.07; 95% CI, 1.01 to 1.12) increased the odds of filling a new ERO prescription. Neuraxial anesthesia (OR, 0.79; 95% CI, 0.74 to 0.84), peripheral nerve block (OR, 0.84; 95% CI, 0.79 to 0.89), and acute pain service involvement (OR, 0.77; 95% CI, 0.70 to 0.85) were protective against filling a new ERO prescription. Substantial variation was found across hospitals (VPC, 46%; 95% CI, 0.4 to 0.54; and MOR, 9.3; 95% CI, 6.57 to 15.27) and surgeons (VPC, 26%; 95% CI, 0.24 to 0.26; and MOR, 5.3; 95% CI, 4.63 to 6.11), with minimal anesthetist-level variation (VPC, 1%; 95% CI, 0.010 to 0.011; and MOR, 1.4; 95% CI, 1.36 to 1.46). Patient-level factors explained a minority of variation. CONCLUSIONS: One in 10 patients fills an ERO prescription after total hip or knee arthroplasty, a practice with high variation that is predominantly driven by institutional and surgical practice patterns rather than patient factors. Future research should explore institutional stewardship, standardized discharge protocols, and multidisciplinary engagement to reduce unnecessary postoperative exposure to EROs.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Malone JL, Tierney SL, McGinn RN, et al. A Population-based Cross-sectional Analysis of Extended-release Opioid Dispensing Incidence, Prognostic Factors, and Variation after Total Joint Arthroplasty. Anesthesiology. 2026. PMID: 42018768. doi:10.1097/ALN.0000000000006107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。